ScreenerHero

RNAAtrium Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · atriumtherapeutics.com
13.20USD-3.72%Mkt Cap: 225.79M $P/E: —

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stag…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap225.79M $
Enterprise Value-31.63M $
Revenue (TTM)35.84M $
Gross Profit-20.20M $
Net Income (TTM)-76.68M $
Revenue/Share2.095 USD
Last Price13.20 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.67
PEG—
EV/EBITDA0.46
EV/Revenue-0.88
P/S6.43
P/B0.98
EPS (TTM)-5.34
EPS (Forward)-8.06
52W Range
11.1437% of range16.77
52W High16.77 USD
52W Low11.14 USD
Profitability
Gross Margin-56.37%
Oper. Margin-752.93%
EBITDA Margin-191.22%
Profit Margin-411.88%
ROE-36.99%
ROA-27.55%
Growth
Revenue Growth-21.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.13M $
CapEx (TTM)1.45M $
FCF Margin—
FCF Yield—
Net Debt-262.22M $
Net Debt/EBITDA3.83
Balance Sheet
Debt/Equity0.02
Current Ratio8.73
Quick Ratio8.38
Book Value/Sh13.69 USD
Cash/Share15.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.00 USD
Upside (mean)+89.4%
Target Range25.00 USD – 25.00 USD
# Analysts4
Ownership
Shares Out.17.11M
Float15.09M
Insiders4.27%
Institutions84.88%
Short Interest
Short Ratio20.9d
Short % Out.20.54%
Shares Short3.59M
Short (prev mo.)3.66M
Technical
SMA 5012.44 (+6.1%)
SMA 20013.03 (+1.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)144.99K
Avg Vol (10d)158.35K
Technical Indicators
RSI (14)60.8
MACD0.2892
MACD Signal0.1017
MACD Hist.+0.1875
BB Upper13.73 USD
BB Middle12.21 USD
BB Lower10.69 USD
BB Width24.91%
ATR (14)0.4790 USD
Vol Ratio (20d)1.31x